Semaglutide reduces heart attack risk by 20%
Irish Examiner — May 14, 2024, 12:00 PM UTC
Summary: A study presented at the European Congress of Obesity revealed that participants taking semaglutide had a 20% lower risk of heart attack, stroke, or death due to cardiovascular disease. The research involved 17,604 adults across 41 countries, showing promising cardiovascular benefits regardless of weight loss. Semaglutide could be a groundbreaking medical breakthrough akin to statins, potentially transforming chronic diseases. Participants on semaglutide lost more weight than those on a placebo.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.